ImmuPharma (LON:IMM) Shares Down 15.3% - Here's Why

Key Points

• ImmuPharma's shares fell by 15.3% during mid-day trading, dropping to GBX 14.90 ($0.20) from a previous close of GBX 17.60 ($0.24).
• Approximately 30.5 million shares were traded, representing a 263% increase over the average daily volume.
• The company reported a negative earnings per share of GBX (0.38) last quarter, with analysts predicting a significant loss of -339.00 for the current year.

ImmuPharma plc (LON:IMM - Get Free Report) was down 15.3% during mid-day trading on Tuesday . The stock traded as low as GBX 14.50 ($0.20) and last traded at GBX 14.90 ($0.20). Approximately 30,500,184 shares traded hands during trading, an increase of 263% from the average daily volume of 8,394,409 shares. The stock had previously closed at GBX 17.60 ($0.24).

ImmuPharma Trading Down 15.3%

The company has a fifty day simple moving average of GBX 3.43 and a 200-day simple moving average of GBX 3.01. The stock has a market cap of £74.46 million, a price-to-earnings ratio of -1,674.16 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.